These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 13129490)

  • 41. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
    Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
    Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
    Hoskins P; Eisenhauer E; Vergote I; Dubuc-Lissoir J; Fisher B; Grimshaw R; Oza A; Plante M; Stuart G; Vermorken J
    J Clin Oncol; 2000 Dec; 18(24):4038-44. PubMed ID: 11118464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Workshop: options for therapy in ovarian cancer.
    Herzog TJ; Holloway RW; Stuart GC
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S45-50. PubMed ID: 13129496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
    Chang SJ; Hodeib M; Chang J; Bristow RE
    Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Ovarian carcinoma: current therapeutic aspects. A review].
    Buser K; Hänggi W; Greiner R; Schatzmann E
    Schweiz Med Wochenschr; 1990 Nov; 120(44):1617-32. PubMed ID: 2251477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
.
    Zheng X; Zhu Y; Zhao Y; Feng S; Zheng C
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):753-760. PubMed ID: 28737125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
    Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
    Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis and Treatment of Ovarian Cancer.
    Orr B; Edwards RP
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):943-964. PubMed ID: 30390767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
    Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
    J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials.
    Zhang H; Jia L; Xu Y; Zhou XC; Kong B; Li D
    J Chemother; 2012 Apr; 24(2):67-73. PubMed ID: 22546760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment options for endometrial cancer: experience with topotecan.
    Holloway RW
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S28-33. PubMed ID: 13129493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.
    Gross-Goupil M; Lokiec F; Lopez G; Tigaud JM; Hasbini A; Romain D; Misset JL; Goldwasser F
    Eur J Cancer; 2002 Sep; 38(14):1888-98. PubMed ID: 12204671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ovarian cancer: a brief historical overview of intraperitoneal trials.
    Kwa M; Muggia F
    Ann Surg Oncol; 2014 May; 21(5):1429-34. PubMed ID: 24081795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ovarian-cancer results cause a stir at cancer conference.
    McNamee D
    Lancet; 2000 May; 355(9218):1890. PubMed ID: 10866453
    [No Abstract]   [Full Text] [Related]  

  • 60. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Leiser AL; Chi DS; Ishill NM; Tew WP
    Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.